Newbridge Financial Services Group’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,200
Closed -$3.42K 1307
2025
Q3
$3.42K Hold
1,200
﹤0.01% 1080
2025
Q2
$4.52K Hold
1,200
﹤0.01% 1042
2025
Q1
$5.44K Hold
1,200
﹤0.01% 788
2024
Q4
$8.48K Hold
1,200
﹤0.01% 768
2024
Q3
$9.77K Hold
1,200
﹤0.01% 433
2024
Q2
$7.67K Hold
1,200
﹤0.01% 759
2024
Q1
$9.04K Hold
1,200
﹤0.01% 794
2023
Q4
$11.1K Sell
1,200
-34
-3% -$278 0.01% 713
2023
Q3
$12.5K Hold
1,234
0.01% 762
2023
Q2
$15.4K Hold
1,234
0.01% 775
2023
Q1
$14.4K Hold
1,234
0.01% 821
2022
Q4
$13.1K Hold
1,234
0.01% 844
2022
Q3
$12K Buy
1,234
+1,200
+3,529% +$15.9K 0.01% 836
2022
Q2
$0 Hold
34
﹤0.01% 1421
2022
Q1
$1K Hold
34
﹤0.01% 1377
2021
Q4
$1K Hold
34
﹤0.01% 1327
2021
Q3
$2K Hold
34
﹤0.01% 1177
2021
Q2
$2K Hold
34
﹤0.01% 1274
2021
Q1
$2K Buy
+34
New +$1.65K ﹤0.01% 1170

Other funds holding HCAT

Newbridge Financial Services Group's HCAT Position: Q4 2025 in Review

Newbridge Financial Services Group sold out of Health Catalyst (HCAT) in Q4 2025, closing a stake of 1,200 shares — an estimated $3.42K sold.

Newbridge Financial Services Group first reported a position in HCAT in Q1 2021 and held it in 19 quarters. The position peaked at $15.4K in Q2 2023. 136 funds tracked by Wall St. Rank hold HCAT as of Q4 2025.

  • Newbridge Financial Services Group reported no remaining Health Catalyst position as of Q4 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 1,200 Health Catalyst shares in Q4 2025, an estimated $3.42K.
  • Newbridge Financial Services Group first reported a position in Health Catalyst in Q1 2021 and held it in 19 quarters.
  • Newbridge Financial Services Group's Health Catalyst position peaked at $15.4K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2025.

Based on Newbridge Financial Services Group's 13F filing for Q4 2025, filed 21 Jan 2026.